Trade OncoCyte Corporation - OCX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0674 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
OncoCyte Corp ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 3.0613 |
| Open* | 2.9913 |
| 1-Year Change* | 315.46% |
| Day's Range* | 2.9913 - 3.0813 |
| 52 wk Range | 3.24-19.28 |
| Average Volume (10 days) | 16.99K |
| Average Volume (3 months) | 444.25K |
| Market Cap | 27.11M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 8.24M |
| Revenue | 1.10M |
| EPS | -2.77 |
| Dividend (Yield %) | N/A |
| Beta | 1.59 |
| Next Earnings Date | Nov 8, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 3, 2023 | 3.0613 | 0.0000 | 0.00% | 3.0613 | 3.1113 | 3.0513 |
| Oct 2, 2023 | 3.0213 | -0.1000 | -3.20% | 3.1213 | 3.1213 | 3.0213 |
| Sep 29, 2023 | 3.1213 | -0.0800 | -2.50% | 3.2013 | 3.2013 | 3.1113 |
| Sep 28, 2023 | 3.1913 | 0.0500 | 1.59% | 3.1413 | 3.2213 | 3.1413 |
| Sep 27, 2023 | 3.1113 | 0.0000 | 0.00% | 3.1113 | 3.1113 | 3.1113 |
| Sep 26, 2023 | 3.2513 | 0.0400 | 1.25% | 3.2113 | 3.3213 | 3.2113 |
| Sep 25, 2023 | 3.1913 | -0.0500 | -1.54% | 3.2413 | 3.2413 | 3.1913 |
| Sep 22, 2023 | 3.2113 | 0.0000 | 0.00% | 3.2113 | 3.2113 | 3.2113 |
| Sep 21, 2023 | 3.1113 | -0.0300 | -0.96% | 3.1413 | 3.1913 | 3.0513 |
| Sep 20, 2023 | 3.2313 | 0.0100 | 0.31% | 3.2213 | 3.3313 | 3.2213 |
| Sep 19, 2023 | 3.2913 | -0.0800 | -2.37% | 3.3713 | 3.3713 | 3.2913 |
| Sep 18, 2023 | 3.3313 | 0.1200 | 3.74% | 3.2113 | 3.3813 | 3.1613 |
| Sep 15, 2023 | 3.1713 | -0.0500 | -1.55% | 3.2213 | 3.2213 | 3.1713 |
| Sep 14, 2023 | 3.2713 | 0.0200 | 0.62% | 3.2513 | 3.2913 | 3.2213 |
| Sep 13, 2023 | 3.2913 | 0.0200 | 0.61% | 3.2713 | 3.3413 | 3.2713 |
| Sep 12, 2023 | 3.3413 | 0.1000 | 3.09% | 3.2413 | 3.3913 | 3.2413 |
| Sep 11, 2023 | 3.2213 | -0.0700 | -2.13% | 3.2913 | 3.3213 | 3.2213 |
| Sep 8, 2023 | 3.2881 | 0.0300 | 0.92% | 3.2581 | 3.3681 | 3.2581 |
| Sep 7, 2023 | 3.2781 | -0.1600 | -4.65% | 3.4381 | 3.4381 | 3.2581 |
| Sep 6, 2023 | 3.3481 | 0.0100 | 0.30% | 3.3381 | 3.3581 | 3.2881 |
OncoCyte Corporation Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, November 8, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 OncoCyte Corp Earnings Release Q3 2023 OncoCyte Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0.958 | 2.198 | 1.216 | 0 | 0 |
| Total Operating Expense | 18.955 | 54.782 | 30.927 | 22.392 | 15.202 |
| Selling/General/Admin. Expenses, Total | 21.533 | 20.392 | 23.282 | 15.445 | 8.688 |
| Research & Development | 6.965 | 4.807 | 9.378 | 6.794 | 6.514 |
| Operating Income | -17.997 | -52.584 | -29.711 | -22.392 | -15.202 |
| Interest Income (Expense), Net Non-Operating | -0.548 | -0.25 | -1.502 | -0.031 | -0.643 |
| Net Income Before Taxes | -18.612 | -52.871 | -31.186 | -22.426 | -15.754 |
| Net Income After Taxes | -18.612 | -43.61 | -29.932 | -22.426 | -15.754 |
| Net Income Before Extra. Items | -18.612 | -43.61 | -29.932 | -22.426 | -15.754 |
| Net Income | -72.902 | -64.097 | -29.932 | -22.426 | -15.754 |
| Income Available to Common Excl. Extra. Items | -19.132 | -43.61 | -29.932 | -22.426 | -15.754 |
| Income Available to Common Incl. Extra. Items | -73.422 | -64.097 | -29.932 | -22.426 | -15.754 |
| Diluted Net Income | -73.422 | -64.097 | -29.932 | -22.426 | -15.754 |
| Diluted Weighted Average Shares | 5.54 | 4.446 | 3.2739 | 2.5648 | 1.8925 |
| Diluted EPS Excluding Extraordinary Items | -3.45343 | -9.80882 | -9.14261 | -8.74376 | -8.32444 |
| Diluted Normalized EPS | 0.19007 | -9.61715 | -9.05883 | -8.68411 | -8.32444 |
| Other, Net | -0.067 | -0.037 | 0.027 | -0.003 | 0.091 |
| Total Extraordinary Items | -54.29 | -20.487 | |||
| Unusual Expense (Income) | 20.185 | 1.311 | 0.422 | 0.153 | |
| Revenue | 0.958 | 2.198 | 1.216 | ||
| Cost of Revenue, Total | 0.976 | 0.778 | 1.855 | ||
| Gross Profit | -0.018 | 1.42 | -0.639 | ||
| Other Operating Expenses, Total | -31.019 | 27.266 | -4.01 | ||
| Depreciation / Amortization | 0.315 | 0.228 | |||
| Total Adjustments to Net Income | -0.52 | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.463 | 0.297 | 0.958 | 1.017 | 0.237 |
| Revenue | 0.463 | 0.297 | 0.958 | 1.017 | 0.237 |
| Cost of Revenue, Total | 0.191 | 0.287 | 0.976 | 2.191 | 0.206 |
| Gross Profit | 0.272 | 0.01 | -0.018 | -1.174 | 0.031 |
| Total Operating Expense | 8.757 | -5.553 | 18.955 | 10.238 | 1.863 |
| Selling/General/Admin. Expenses, Total | 3.855 | 4.107 | 21.533 | 9.21 | 5.448 |
| Research & Development | 1.924 | 1.764 | 6.965 | 4.125 | 2.363 |
| Other Operating Expenses, Total | 1.795 | -18.307 | -31.019 | -6.142 | -6.359 |
| Operating Income | -8.294 | 5.85 | -17.997 | -9.221 | -1.626 |
| Interest Income (Expense), Net Non-Operating | -0.023 | 0.111 | -0.548 | -0.174 | -0.016 |
| Other, Net | -0.016 | -0.002 | -0.067 | 0.062 | 0.278 |
| Net Income Before Taxes | -8.333 | 5.959 | -18.612 | -9.333 | -1.364 |
| Net Income After Taxes | -8.333 | 5.959 | -18.612 | -9.333 | -1.364 |
| Net Income Before Extra. Items | -8.333 | 5.959 | -18.612 | -9.333 | -1.364 |
| Net Income | -8.333 | 3.033 | -72.902 | -9.333 | -8.3 |
| Income Available to Common Excl. Extra. Items | -8.644 | 5.729 | -19.132 | -9.555 | -1.436 |
| Income Available to Common Incl. Extra. Items | -8.644 | 2.803 | -73.422 | -9.555 | -8.372 |
| Diluted Net Income | -8.644 | 2.803 | -73.422 | -9.555 | -8.372 |
| Diluted Weighted Average Shares | 8.09 | 7.56 | 5.54 | 5.9305 | 5.652 |
| Diluted EPS Excluding Extraordinary Items | -1.06848 | 0.7578 | -3.45343 | -1.61116 | -0.25407 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.98937 | 1.58228 | 0.19007 | -1.51707 | -0.23213 |
| Unusual Expense (Income) | 0.64 | 6.233 | 20.185 | 0.558 | 0.124 |
| Depreciation / Amortization | 0.352 | 0.363 | 0.315 | 0.296 | 0.081 |
| Total Extraordinary Items | 0 | -2.926 | -54.29 | -6.936 | |
| Total Adjustments to Net Income | -0.311 | -0.23 | -0.52 | -0.222 | -0.072 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 25.536 | 39.143 | 9.226 | 22.956 | 8.642 |
| Cash and Short Term Investments | 20.426 | 36.509 | 7.818 | 22.451 | 8.462 |
| Cash & Equivalents | 19.993 | 35.605 | 7.143 | 22.072 | 8.034 |
| Short Term Investments | 0.433 | 0.904 | 0.675 | 0.379 | 0.428 |
| Prepaid Expenses | 0.977 | 0.693 | 1.205 | 0.505 | 0.18 |
| Other Current Assets, Total | 2.121 | ||||
| Total Assets | 100.091 | 159.563 | 55.419 | 39.859 | 9.518 |
| Property/Plant/Equipment, Total - Net | 10.851 | 8.527 | 6.524 | 3.728 | 0.614 |
| Property/Plant/Equipment, Total - Gross | 15.047 | 11.242 | 7.964 | 4.071 | 1.562 |
| Accumulated Depreciation, Total | -4.196 | -2.715 | -1.44 | -0.343 | -0.948 |
| Intangibles, Net | 61.633 | 91.245 | 15.009 | 0 | |
| Other Long Term Assets, Total | 2.071 | 1.964 | 2.056 | 2.211 | 0.262 |
| Total Current Liabilities | 12.106 | 14.12 | 8.996 | 4.44 | 5.561 |
| Accounts Payable | 1.253 | 2.447 | 0.432 | 0.469 | 0.166 |
| Accrued Expenses | 8.731 | 10.256 | 5.423 | 2.769 | 2.109 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.117 | 1.417 | 2.541 | 1.196 | 1.185 |
| Other Current Liabilities, Total | 2.005 | 0.6 | 0.006 | 2.101 | |
| Total Liabilities | 60.497 | 94.346 | 21.936 | 9.021 | 6.095 |
| Total Long Term Debt | 0 | 0.117 | 1.729 | 1.963 | 0.534 |
| Capital Lease Obligations | 0 | 0.117 | 0.221 | 0.058 | 0.187 |
| Total Equity | 39.594 | 65.217 | 33.483 | 30.838 | 3.423 |
| Preferred Stock - Non Redeemable, Net | 5.302 | 0 | 0 | ||
| Common Stock | 294.929 | 252.954 | 157.16 | 124.583 | 74.742 |
| Retained Earnings (Accumulated Deficit) | -260.676 | -187.774 | -123.677 | -93.745 | -71.319 |
| Other Equity, Total | 0.039 | 0.037 | 0 | ||
| Total Liabilities & Shareholders’ Equity | 100.091 | 159.563 | 55.419 | 39.859 | 9.518 |
| Total Common Shares Outstanding | 118.644 | 92.232 | 69.117 | 57.032 | 40.664 |
| Long Term Debt | 0 | 1.508 | 1.905 | 0.347 | |
| Long Term Investments | 0 | 13.417 | 10.964 | ||
| Other Liabilities, Total | 48.391 | 80.109 | 11.211 | 2.618 | |
| Total Receivables, Net | 2.012 | 1.637 | 0.203 | ||
| Accounts Receivable - Trade, Net | 2.012 | 1.437 | 0.203 | ||
| Goodwill, Net | 0 | 18.684 | 9.187 | ||
| Total Inventory | 0.304 | ||||
| Total Preferred Shares Outstanding | 0.00001 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 15.648 | 25.536 | 36.636 | 49.368 | 24.623 |
| Cash and Short Term Investments | 12.356 | 20.426 | 32.472 | 45.415 | 20.986 |
| Cash & Equivalents | 11.803 | 19.993 | 32.053 | 44.836 | 20.412 |
| Short Term Investments | 0.553 | 0.433 | 0.419 | 0.579 | 0.574 |
| Total Receivables, Net | 1.901 | 2.012 | 1.99 | 1.802 | 2.122 |
| Accounts Receivable - Trade, Net | 1.901 | 2.012 | 1.99 | 1.802 | 2.122 |
| Prepaid Expenses | 0.97 | 0.977 | 2.174 | 2.151 | 1.515 |
| Total Assets | 82.8 | 100.091 | 157.344 | 171.051 | 146.273 |
| Property/Plant/Equipment, Total - Net | 8.424 | 10.851 | 11.593 | 11.576 | 10.651 |
| Property/Plant/Equipment, Total - Gross | 13.196 | 15.047 | 15.73 | 15.197 | 13.769 |
| Accumulated Depreciation, Total | -4.772 | -4.196 | -4.137 | -3.621 | -3.117 |
| Goodwill, Net | 0 | 18.684 | 18.684 | 18.684 | |
| Intangibles, Net | 56.661 | 61.633 | 88.365 | 89.341 | 90.317 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 2.067 | 2.071 | 2.066 | 2.082 | 1.998 |
| Total Current Liabilities | 9.43 | 12.106 | 12.952 | 14.154 | 13.955 |
| Accounts Payable | 1.395 | 1.253 | 1.826 | 2.465 | 2.584 |
| Accrued Expenses | 7.71 | 8.731 | 11.013 | 11.005 | 10.319 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.089 | 0.117 | 0.113 | 0.684 | 1.052 |
| Other Current Liabilities, Total | 0.236 | 2.005 | |||
| Total Liabilities | 39.335 | 60.497 | 75.411 | 82.954 | 89.306 |
| Total Long Term Debt | 0 | 0 | 0.031 | 0.06 | 0.089 |
| Long Term Debt | |||||
| Capital Lease Obligations | 0 | 0 | 0.031 | 0.06 | 0.089 |
| Other Liabilities, Total | 29.905 | 48.391 | 62.428 | 68.74 | 75.262 |
| Total Equity | 43.465 | 39.594 | 81.933 | 88.097 | 56.967 |
| Common Stock | 295.533 | 294.929 | 292.536 | 289.649 | 254.994 |
| Retained Earnings (Accumulated Deficit) | -257.643 | -260.676 | -215.698 | -206.437 | -198.065 |
| Total Liabilities & Shareholders’ Equity | 82.8 | 100.091 | 157.344 | 171.051 | 146.273 |
| Total Common Shares Outstanding | 119.279 | 118.644 | 118.619 | 118.609 | 92.247 |
| Other Equity, Total | 0.043 | 0.039 | 0.019 | 0.031 | 0.038 |
| Preferred Stock - Non Redeemable, Net | 5.532 | 5.302 | 5.076 | 4.854 | |
| Other Current Assets, Total | 0.421 | 2.121 | |||
| Total Preferred Shares Outstanding | 0.00001 | 0.00001 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -72.902 | -64.097 | -29.932 | -22.426 | -15.754 |
| Cash From Operating Activities | -45.568 | -35.941 | -25.98 | -19.715 | -11.649 |
| Cash From Operating Activities | 1.528 | 0.844 | 0.313 | 0.344 | 0.438 |
| Amortization | 3.692 | 3.361 | 0.081 | 0 | 0.121 |
| Non-Cash Items | 24.056 | 35.415 | 4.413 | 3.922 | 2.553 |
| Changes in Working Capital | -1.942 | -2.203 | 0.399 | -1.555 | 0.993 |
| Cash From Investing Activities | -4.34 | -13.961 | -11.748 | -12.415 | -0.031 |
| Capital Expenditures | -4.34 | -2.247 | -1.227 | -0.918 | -0.031 |
| Other Investing Cash Flow Items, Total | 0 | -11.714 | -10.521 | -11.497 | 0 |
| Cash From Financing Activities | 35.806 | 78.364 | 22.799 | 47.868 | 12.114 |
| Financing Cash Flow Items | -0.483 | -3.065 | -0.132 | -3.288 | -0.355 |
| Issuance (Retirement) of Stock, Net | 37.718 | 82.963 | 22.236 | 49.793 | 13.65 |
| Issuance (Retirement) of Debt, Net | -1.429 | -1.534 | 0.695 | 1.363 | -1.181 |
| Net Change in Cash | -14.102 | 28.462 | -14.929 | 15.738 | 0.434 |
| Cash Interest Paid | 0.024 | 0.114 | 0.209 | 0.171 | 0.142 |
| Deferred Taxes | 0 | -9.261 | -1.254 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 3.033 | -72.902 | -27.924 | -18.591 | -10.291 |
| Cash From Operating Activities | -9.672 | -45.568 | -35.92 | -24.568 | -13.277 |
| Cash From Operating Activities | 0.45 | 1.528 | 1.062 | 0.671 | 0.287 |
| Amortization | 0.022 | 3.692 | 2.88 | 1.904 | 0.928 |
| Deferred Taxes | 0 | 0 | 0 | ||
| Non-Cash Items | -11.212 | 24.056 | -9.589 | -6.742 | -2.309 |
| Cash Interest Paid | 0 | 0.024 | 0.024 | 0.021 | 0.013 |
| Changes in Working Capital | -1.965 | -1.942 | -2.349 | -1.81 | -1.892 |
| Cash From Investing Activities | 0 | -4.34 | -3.538 | -2.679 | -1.561 |
| Capital Expenditures | 0 | -4.34 | -3.538 | -2.679 | -1.561 |
| Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
| Cash From Financing Activities | -0.028 | 35.806 | 35.906 | 36.478 | -0.355 |
| Financing Cash Flow Items | 0 | -0.483 | -0.483 | -0.483 | -0.001 |
| Issuance (Retirement) of Stock, Net | 0 | 37.718 | 37.718 | 37.718 | 0.031 |
| Issuance (Retirement) of Debt, Net | -0.028 | -1.429 | -1.329 | -0.757 | -0.385 |
| Net Change in Cash | -9.7 | -14.102 | -3.552 | 9.231 | -15.193 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
OncoCyte Corporation Company profile
About OncoCyte Corp
Oncocyte Corporation is a molecular diagnostics company. The Company is engaged in developing and commercializing laboratory-developed tests (LDTs) to serve unmet medical needs across the cancer care continuum. The LTDs provide actionable information to physicians and patients to optimize treatment decisions, including the selection of immunotherapy. The Company focuses on the development of a non-invasive confirmatory blood test for lung cancer called DetermaDx. The DetermaDx is the test to predict a post-surgery patient’s risk of cancer recurrence and their response to chemotherapy in early-stage lung cancer. Its development pipeline includes TheraSure CNI Monitor, which is a blood-based test for immunotherapy monitoring, and TheraSure Transplant Monitor, a solid organ transplantation monitoring test. Its other DetermaIO, DetermaCNI, DetermaMx, Keytruda, Opdivo, Tecentriq and Imfinzi.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, OncoCyte Corp revenues increased from $1.2M to $7.7M. Net loss increased from $29.9M to $64.1M. Revenues reflect DetermaRx segment increase from $547K to $2.5M, Pharma Services segment increase from $669K to $1.5M, United States segment increase from $742K to $3.5M. Higher net loss reflects Fair Value Adjustments on Other Assets increase from $4M (income) to $27.3M (expense).
| Industry: | Bio Therapeutic Drugs |
15 Cushing
IRVINE
CALIFORNIA 92618
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com